IMPLICATIONS of GLOBAL PRICING POLICIES on ACCESS to INNOVATIVE DRUGS: The CASE of TRASTUZUMAB in SEVEN LATIN AMERICAN COUNTRIES

International Journal of Technology Assessment in Health Care

Volumn 31, Issue 1-2, 2015, Pages 2-11

  Pichon Riviere, Andres ^a,b   Garay, Osvaldo Ulises ^a   Augustovski, Federico ^a,b   Vallejos, Carlos ^c   Huayanay, Leandro ^d   Bueno, Maria Del Pilar Navia ^e   Rodriguez, Alarico ^f   De Andrade, Carlos José Coelho ^g   Buendía, Jefferson Antonio ^h   Drummond, Michael ⁱ  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

^d UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^e UNIVERSIDAD DE SAN ANDRÉS   (Argentina)

^f Fondo Nacional de Recursos   (United States)

^g INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^h UNIVERSIDAD DE ANTIOQUIA   (Colombia)

ⁱ UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Cost utility; Cost effectiveness; drug pricing; Latin America; trastuzumab

Indexed keywords

COST BENEFIT ANALYSIS; COST EFFECTIVENESS; DEVELOPING COUNTRIES; DIAGNOSIS; DISEASES; MARKOV PROCESSES; MONOCLONAL ANTIBODIES; SENSITIVITY ANALYSIS;

COST UTILITY; HEALTH TECHNOLOGY ASSESSMENTS; LATIN AMERICA; PROBABILISTIC SENSITIVITY ANALYSIS; QUALITY ADJUSTED LIFE YEARS; TRANSITION PROBABILITIES; TRASTUZUMAB; WORLD HEALTH ORGANIZATION;

COSTS;

TRASTUZUMAB; ANTINEOPLASTIC AGENT;

ARGENTINA; ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; BOLIVIA; BRAZIL; BREAST CANCER; CANCER PROGNOSIS; CHILE; COLOMBIA; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; GROSS NATIONAL PRODUCT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; PERU; PURCHASING; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; SENSITIVITY ANALYSIS; URUGUAY; BREAST NEOPLASMS; COST; COST BENEFIT ANALYSIS; DEVELOPING COUNTRY; ECONOMICS; HUMAN; MARKOV CHAIN; QUALITY OF LIFE; SOUTH AND CENTRAL AMERICA; STATISTICAL MODEL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DEVELOPING COUNTRIES; HUMANS; LATIN AMERICA; MARKOV CHAINS; MODELS, ECONOMETRIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TRASTUZUMAB;

EID: 84937073467     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462315000094     Document Type: Article

References (59)

1. United Nations. General Assembly. Prevention and control of noncommunicable. Report of the Secretary-General 2011. http: //www. un. org/ga/search/view-doc. asp?symbol=A/66/83&Lang=E (accessed March 15, 2013)
2. World Health Organization. Preventing chronic diseases: A vital investment: WHO global report. WHO Library Cataloguingin-Publication Data 2005. http: //www. who. int/chp/chronic-disease- report/contents/foreword. pdf (accessed March 15, 2013)
3. Howitt P, Darzi A, Yang GZ, et al. Technologies for global health. Lancet. 2012; 380: 507-535
4. World Health Organization. Research and development to meet health needs in developing countries: Strengthening global financing and coordination. Report of the consultative expert working group on research and development: Financing and coordination. 2012. http: //www. who. int/phi/CEWG-Report-5-April-2012. pdf (accessed March 15, 2013)
5. World Health Organization. Report of the Workshop on Differential Pricing & Financing of Essential Drugs. 2001. http: //apps. who. int/medicinedocs/en/d/Jh2951e/ (accessed March 15, 2013)
6. Morel CM, McGuire A, Mossialos E. The level of income appears to have no consistent bearing on pharmaceutical prices across countries. Health Aff (Millwood). 2011; 30: 1545-1552
7. Gelders S, Ewen M, Noguchi N, Laing R. Price, availability and affordability. An international comparison of chronic disease medicines. Background report prepared for theWHOPlanning Meeting on the Global Initiative for Treatment of ChronicDiseases held in Cairo in December 2005 2006. http: //apps. who. int/medicinedocs/index/assoc/s14135e/s14135e (accessed March 10, 2013)
8. Tobar F, Charreau J. Comparación internacional del precio de los medicamentos de alto costo. Argentina, Páses del Cono sur, España e Inglaterra. 2011. http: //www. fsg. org. ar/publicaciones/Precio%20de% 20los%20medicamentos%20de%20alto%20costo. pdf (accessed March 15, 2013)
9. World Health Organization. The World Health Report-Health Systems Financing: The path to universal coverage. 2010. http: //www. who. int/ entity/whr/2010/whr10-en. pdf (accessed March 15, 2013)
10. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 94: 153-156
11. Lozano-Ascencio R, Gomez-Dantes H, Lewis S, Torres-Sanchez L, Lopez-Carrillo L. [Breast cancer trends in Latin America and the Caribbean]. Salud Publica Mex. 2009; 51(Suppl 2): s147-s156
12. Plosker GL, Keam SJ. Trastuzumab: A review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs. 2006; 66: 449-475
13. Liao N, Zhang GC, Li XR, Yao M, Wang K. [A meta-analysis of neoadjuvant chemotherapy combined with trastuzumab for HER2-positive breast cancers]. Nan Fang Yi Ke Da Xue Xue Bao. 2009; 29: 943-945
14. Chan AL, Leung HW, Lu CL, Lin SJ. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: A systematic review. Ann Pharmacother. 2009; 43: 296-303
15. Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: An analysis based on updated results from the HERA Trial. Value Health. 2009; 12: 641-648
16. Lidgren M, Jonsson B, Rehnberg C, Willking N, Bergh J. Costeffectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol. 2008; 19: 487-495
17. Liberato NL, Marchetti M, Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2007; 25: 625-633
18. Garrison LP Jr, Lubeck D, Lalla D, et al. Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer. Cancer. 2007; 110: 489-498
19. Shiroiwa T, Fukuda T, Shimozuma K, Ohashi Y, Tsutani K. The modelbased cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: Based on 2-year follow-up HERA trial data. Breast Cancer Res Treat. 2008; 109: 559-566
20. Norum J, Olsen JA, Wist EA, Lonning PE. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncol. 2007; 46: 153-164
21. Fagnani F, Colin X, Arveux P, Coudert B, Misset JL. [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]. Bull Cancer. 2007; 94: 711-720
22. Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the real-world costeffectiveness of adjuvant trastuzumab in HER-2/neu positive breast cancer. Oncologist. 2012; 17: 164-171
23. Purmonen TT, Pankalainen E, Turunen JH, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHerTrial. Acta Oncol. 2011; 50: 344-352
24. Hall PS, Hulme C, McCabe C, et al. Updated cost-effectiveness analysis of trastuzumab for early breast cancer: A UK perspective considering duration of benefit, long-term toxicity and pattern of recurrence. Pharmacoeconomics. 2011; 29: 415-432
25. Sullivan R, Peppercorn J, Sikora K, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011; 12: 933-980
26. Banta D. Health technology assessment in Latin America and the Caribbean. Int J Technol Assess Health Care. 2009; 25(Suppl 1): 253-254
27. Pichon-Riviere A, Augustovski F, Rubinstein A, et al. Health technology assessment for resource allocation decisions: Are key principles relevant for Latin America? Int J Technol Assess Health Care. 2010; 26: 421-427
28. Di Ruggiero E, Zarowsky C, Frank J, et al. Coordinating Canada's research response to global health challenges: The Global Health Research Initiative. Can J Public Health. 2006; 97: 29-31
29. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices-overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012; 15: 796-803
30. Sachs JD. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. WHO Library Cataloguing-in-Publication Data 2001. http: //whqlibdoc. who. int/publications/2001/924154550x. pdf (accessed March 10, 2013)
31. Barajas RE, Rós PR. Guá de Evaluación de Insumos para la Salud. In: Dirección General Adjunta de Priorización Comisión Interinstitucional del Cuadro Básico y Catálogo de Insumos del Sector Salud, editor. Mexico; 2011. http: //www. csg. salud. gob. mx/ descargas/pdfs/cuadro-basico/guia-eval-insumos11052011. pdf (accessed March 10, 2013)
32. Ministerio de Salud de Chile. Guá Metodológica para la Evaluaci ón Económica de Intervenciones en Salud en Chile. In: Departamento de Economá de la Salud Subsecretará de Salud Pública, editor. Santiago de Chile; 2013. http: //desal. minsal. cl/wp-content/ uploads/2013/09/EE-FINAL-web. pdf (accessed October 4, 2013)
33. Instituto de Evaluación Tecnológica en Salud (IETS). Manual para la elaboración de evaluaciones económicas en salud. Bogotá; 2014. http: //www. iets. org. co/manuales/Manuales/Manual%20evaluacio%CC %81n%20econo%CC%81mica%20web%2030%20sep. pdf (accessed October 14, 2013)
34. George B, Harris A, Mitchell A. Cost-effectiveness analysis and the consistency of decision making: Evidence from pharmaceutical reimbursement in australia (1991 to 1996). Pharmacoeconomics. 2001; 19: 1103-1109
35. Augustovski F, Garay OU, Pichon-Riviere A, Rubinstein A, Caporale JE. Economic evaluation guidelines in Latin America: A current snapshot. Expert Rev Pharmacoecon Outcomes Res. 2010; 10: 525-537
36. Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12: 236-244
37. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: Arandomised controlled trial. Lancet. 2007; 369: 29-36
38. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672
39. Paul Kind, Richard Brooks, Rabin R, editors. EQ-5D concepts and methods: A developmental history. New York: Springer; 2005
40. Calvert MJ, Freemantle N, Cleland JG. The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. Eur J Heart Fail. 2005; 7: 243-251
41. International Agency for Research on Cancer. Globocan 2008 Cancer Incidence, Mortality and Prevalence Worldwide in 2008. http: // globocan. iarc. fr/ (accessed March 10, 2013)
42. Bland KI, Menck HR, Scott-Conner CE, et al. The National Cancer Data Base 10-year survey of breast carcinoma treatment at hospitals in the United States. Cancer. 1998; 83: 1262-1273
43. Paik S, Bryant J, Tan-Chiu E, et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst. 2000; 92: 1991-1998
44. Prieto MM, Torres CS. Situación epidemiológica del cáncer de mama en Chile 1994-2003. Epidemiologic situation of breast cancer in Chile 1994-2003. Rev Méd Clń Condes. 2006; 17: 142-148
45. Piñeros M, Sánchez R, Cendales R, et al. Caractersticas sociodemogr áficas, clńicas y de la atención de mujeres con cáncer de mama en Bogotá. Social, Demographic and Clinical Features in Women with Breast Cancer attending Health Services in Bogotá. Rev Colomb Cancerol. 2008; 12: 181-190
46. Solidoro Andrés. Cáncer en el Perú del 2000: hechos, cifras, realidades DIAGNOSTICO. 2001; 40: 306-317. http: //www. fihu-diagnostico. org. pe/revista/numeros/2001/novdic01/306-317. html (accessed March 10, 2013)
47. Juarez AM. Edad y estadio de la mujeres con cancer de mama, hospitales públicos, Córdoba 1998/2003. Age and stage of the with breast cancer. Public hospitals, Cordoba 1998-2003. Rev Esc Salud Pública. 2009; 13: 33-42
48. Vázquez T, Krygier G, Barrios E, et al. Análisis de sobrevida de una población con cáncer de mama y su relación con factores pronósticos: estudio de 1. 311 pacientes seguidas durante 230 meses: trabajo de equipo multidisciplinario. Survival analysis i a populationwith breast cancer and its pronostic factors: 230 months-follow up in 1. 311 women. Rev Méd Urug. 2005; 21: 107-121
49. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007; 25: 634-641
50. Ministério da Sáude do Brasil. Secretaria de Ciência, Tecnologia e InsumosEstrat égicos. Relatório de recomendaç ão da ComissãoNacional de Incorporaç ão de Tecnologias no SUS-CONITEC-07: trastuzumabeparatratamento do câncer de mama inicial. 2012. http: //portal. saude. gov. br/portal/arquivos/pdf/Trastuzumabe-cainicial-final. pdf (accessed March 15, 2013)
51. Danzon PM, Towse A, Mulcahy AW. Setting cost-effectiveness thresholds as a means to achieve appropriate drug prices in rich and poor countries. Health Aff (Millwood). 2011; 30: 1529-1538
52. Goss PE, Lee BL, Badovinac-Crnjevic T, et al. Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 2013; 14: 391-436
53. World Health Organization. WHO Guideline on Country Pharmaceutical Pricing Policies. 2013: Geneva. http: //www. who. int/ childmedicines/publications/WHO-GPPP. pdf?ua=1 (accessed October 2014)
54. Knaul FM, Frenk J, Shulman L. Closing the cancer divide: A blueprint to expand access in low and middle income countries. Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries. Boston, MA: Harvard Global Equity Initiative; 2011
55. Instituto de Efectividad Clńica y Sanitaria (IECS). Base de datos de Costos Sanitarios Argentinos. 2011. http: //www. iecs. org. ar/ iecs-buscador-costos. php (accessed March 10, 2013)
56. Chile. Ministerio de Salud. Subsecretará de Salud P. Estudio costo-efectividad de intervenciones en salud: informe final. 2010. http: //desal. minsal. cl/wp-content/uploads/2013/09/01CostoEfectividad. pdf (accessed March 15, 2013)
57. Martinez JI DJ, Diaz S. et al. Costos del uso de trastuzumab para cáncer de mama metastásico en el Instituto Nacional de Cancerologá. Serie de casos. Rev Colomb Cancerol. 2007; 11(3): 189-192
58. Sánchez-Castillo JO. Estudio de costo-efectividad del uso de trastuzumab como tratamiento adjuvante del cáncer de mama temprano HER 2 positivo en el Instituto Nacional de Cancerologá, desde el punto de vista del pagador (tesis). Bogota, D. C. : Universidad Nacional de Colombia; 2008
59. Instituto Nacional de Enfermedades Neoplasicas "Dr. Eduardo Caceres Graziani". Tarifario INEN. 2012. http: //www. inen. sld. pe/portal/ documentos/pdf/tarifario-institucional/31012012-Tarif-Instit-2012. pdf (accessed March 11, 2013)